A Study of QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer
Clinical trial NCT06509971 · UNKNOWN
Trial details
- NCT number
- NCT06509971
- Sponsor
- West China Second University Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-07-01
- Primary completion
- 2026-02-01
- Enrollment
- 39
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.